UiPath (NYSE:PATH) PT Raised to $27.00

UiPath (NYSE:PATH) had its price target increased by equities research analysts at Evercore ISI from $24.00 to $27.00 in a research report issued on Thursday, Benzinga reports. The firm currently has an “in-line” rating on the healthcare company’s stock. Evercore ISI’s price target points to a potential upside of 17.06% from the stock’s previous close.

A number of other analysts have also weighed in on PATH. JPMorgan Chase & Co. upgraded UiPath from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $22.00 to $28.00 in a report on Thursday. Canaccord Genuity Group upped their target price on UiPath from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Friday. TD Cowen upped their target price on UiPath from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday. Barclays upped their target price on UiPath from $23.00 to $25.00 and gave the stock an “equal weight” rating in a report on Friday. Finally, BMO Capital Markets upped their target price on UiPath from $19.00 to $24.00 and gave the stock a “market perform” rating in a report on Friday, December 1st. Nine investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $27.13.

UiPath Stock Up 1.4 %

NYSE:PATH traded up $0.32 during midday trading on Thursday, hitting $23.07. The stock had a trading volume of 9,842,354 shares, compared to its average volume of 10,074,664. UiPath has a one year low of $12.38 and a one year high of $27.87. The company has a market capitalization of $13.06 billion, a price-to-earnings ratio of -135.46 and a beta of 0.97. The stock has a 50-day moving average of $23.52 and a 200 day moving average of $20.70.

Insiders Place Their Bets

In other UiPath news, CFO Ashim Gupta sold 70,000 shares of the stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $23.02, for a total transaction of $1,611,400.00. Following the sale, the chief financial officer now directly owns 788,148 shares of the company’s stock, valued at approximately $18,143,166.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other UiPath news, CFO Ashim Gupta sold 70,000 shares of the stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $23.02, for a total transaction of $1,611,400.00. Following the sale, the chief financial officer now directly owns 788,148 shares of the company’s stock, valued at approximately $18,143,166.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Rich Wong sold 200,000 shares of the firm’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $23.12, for a total value of $4,624,000.00. Following the sale, the director now owns 429,418 shares in the company, valued at $9,928,144.16. The disclosure for this sale can be found here. In the last three months, insiders have sold 411,000 shares of company stock valued at $9,418,670. Company insiders own 31.03% of the company’s stock.

Institutional Investors Weigh In On UiPath

A number of institutional investors have recently modified their holdings of PATH. Royal London Asset Management Ltd. increased its position in shares of UiPath by 5.9% during the third quarter. Royal London Asset Management Ltd. now owns 139,544 shares of the healthcare company’s stock worth $2,388,000 after purchasing an additional 7,742 shares in the last quarter. Barclays PLC increased its position in shares of UiPath by 55.2% during the second quarter. Barclays PLC now owns 968,036 shares of the healthcare company’s stock worth $16,039,000 after purchasing an additional 344,499 shares in the last quarter. O Shaughnessy Asset Management LLC purchased a new stake in shares of UiPath during the third quarter worth approximately $203,000. Invesco Ltd. increased its position in shares of UiPath by 2.8% during the third quarter. Invesco Ltd. now owns 399,181 shares of the healthcare company’s stock worth $6,830,000 after purchasing an additional 10,863 shares in the last quarter. Finally, Symmetry Partners LLC purchased a new stake in shares of UiPath during the fourth quarter worth approximately $205,000. 59.04% of the stock is currently owned by institutional investors and hedge funds.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.